TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sleep interruptions
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: EOLPRO scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in intracanal E. faecalis counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fasting proinsulin/insulin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucagon-stimulated C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fasting and nonfasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean intra-abdominal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal distension
Endpoint domain: Adverse events/effects
Primary endpoint: Maintaining mydriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reduction of ocular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative pupil diameter of 6.0 mm or larger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Duration of hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial load of A actinomycetemcomitans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of implant and prosthesis failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 3-year peri-implant marginal bone level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI25 achievement at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of new bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone-to-graft contact percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed PPB
Endpoint domain: Adverse events/effects
Primary endpoint: log-pEBV DNA as a marker of tumor burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Retention in care at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vitamin B-12 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transferrin receptors concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Food effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinomanometric values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Olfactometric threshold sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxidative stress parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency Medical Services (EMS) use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Alertness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sustained attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of successful nasotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intubation difficulty score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of tracheal intubation attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pulmonary embolism (PE)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in non-inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration in acoustic parameters (jitter, shimmer, HNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of underdiagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of overdiagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of organ failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective ratings on the modified amphetamine scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance on the Continuous Performance Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate and blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of having interstitial cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the intravesical potassium test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the intravesical potassium test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ikigai‐9 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ‐5D‐5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Endothelial progenitor cell (EPC) counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of RA at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for intraoperative supplementary fentanyl
Endpoint domain: Adverse events/effects
Primary endpoint: Time to reach Aldrete 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DeltaCP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in involved areas of duodenal polyposis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of intrauterine infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: TpTe values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TpTe/QT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in MRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in BASDAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cataract progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Progression of root caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of antral waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of phasic pyloric pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amplitude of duodenal waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: walking speed under single- and dual-task conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-stage renal disease (ESRD) risk
Endpoint domain: Mortality/survival
Primary endpoint: Vascular events (VEs) risk
Endpoint domain: Mortality/survival
Primary endpoint: Mortality risk (vascular and non-vascular)
Endpoint domain: Mortality/survival
Primary endpoint: inhaler technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preparedness to manage a COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to achieve goals in managing COPD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smoking cessation associated with screen-detected abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative symptomatic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: foot amputations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Perceived bleeding levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with abortion method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain and cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord blood 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: resin-related complications per prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success, survival, and failure rates of prostheses
Endpoint domain: Mortality/survival
Primary endpoint: gains on measures of print knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastrointestinal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Daily cost reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum retinol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worry about STD infection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Worry about HIV infection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: game performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiofrequency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAS satisfaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC pain and stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological responses (autonomic changes, increased breathing rate, sweating, nausea, cold sensation, heat sensation, fear, panic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriuria rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased pushing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: fewer decelerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of complications per chemotherapy cycles
Endpoint domain: Adverse events/effects
Primary endpoint: LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL-C goals achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein B/A1 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic tacrolimus exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vRNA AAUCMB mean treatment difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Time to 1-mm ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Canadian Cardiovascular Society class for angina pectoris
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychiatric symptoms of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall prevalence of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: serum triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean lymph node harvest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: adequacy of nodal harvest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Memory quotient (MQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volume of hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean swelling reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total minutes per day of vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vigorous physical activity minutes in bouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total accelerometer counts per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of repigmentation (90-100%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLQI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ALLO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absolute mean deviation of INR from the target or therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious haemorrhage cases
Endpoint domain: Adverse events/effects
Primary endpoint: AMP bronchial challenge PC(20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: induced sputum eosinophil cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: elbow extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net muscle phenylalanine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mTOR phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (T(½))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Frey syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Successful reconstructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful detoxification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean withdrawal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in EEM volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Regression of atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: serum magnesium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak average compartment pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: withdrawal suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tachycardia
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive performance impairment
Endpoint domain: Adverse events/effects
Primary endpoint: Carotid bulb intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Osteopontin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological lesion clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Virological response at the end of follow-up period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA nadir level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year FFF rate
Endpoint domain: Mortality/survival
Primary endpoint: Hemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage weight loss during hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average serum potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean depth of chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum potassium elevation
Endpoint domain: Adverse events/effects
Primary endpoint: faecal blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of ulcers > or = 3 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HBV DNA levels <69 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Buck-Gramcko score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: palmar and radial abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: willingness to undergo surgery again
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: vigilance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: short-term memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visual problem solving
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time to exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF burden (percentage of days with documented episodes of paroxysmal AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost per major CV event avoided
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite outcome
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of subjective Frey syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of objective Frey syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Time to control hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of dose adjustments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of hypotensive episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Annual fasting glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of developing impaired fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of vascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in night sweats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carboxyhemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fugl-Meyer Upper Extremity (F-M UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence Measure (FIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: National Institutes of Health Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean work days lost
Endpoint domain: Life impact
Endpoint subdomain: Role functioning